Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib-Lenalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT02897830Phase 2Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Stringent Complete Response Rate at 13 months. Started Aug 2016; status: terminated.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02897830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897830.